Learn about the promising results of triplet therapy in early bladder cancer treatment, offering new hope for patients.

Discover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential ...

Explore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing ...

In October, the U.S. Food and Drug Administration (FDA) granted fast track designation to investigational therapies across a range of cancer types, including lung, prostate, gastrointestinal, and ...

The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

Patients with advanced or recurrent endometrial cancer that progresses after platinum-based chemotherapy and immunotherapy have few effective options. New phase 3 data suggest an antibody-drug ...

The phase 3 DeLLphi-305 trial showed tarlatamab plus durvalumab significantly improved overall and progression-free survival ...

Once again, a major clinical trial has shown that for patients with muscle invasive bladder cancer (MIBC) who were ineligible for or decline cisplatin-based chemotherapy before radical cystectomy, ...

The combination of the individualized neoantigen therapy (INT) intismeran autogene plus pembrolizumab (Keytruda) significantly improved the recurrence-free survival (RFS) compared with placebo plus ...

The claudin 18.2 (CLDN18.2)-targeting antibody drug conjugate (ADC) sonesitatug vedotin significantly improved overall survival (OS) in patients with previously treated advanced or metastatic CLDN18.2 ...